Project Term
–
Project Summary
In December 2024, LLS made an equity investment in Solu Therapeutics to "Support Preclinical and Clinical Development of STX-0712 in hematological malignancies, primarily in CMML."
Solu Therapeutics is a biotechnology company dedicated to developing next-generation therapeutics to eliminate disease-driving cells in cancer, immunology and other therapeutic areas. The company’s proprietary CyTAC (Cytotoxicity Targeting Chimera) and TicTAC (Therapeutic Index Control Targeting Chimera) platforms enable the development of innovative medicines that combine the target-binding capability of small molecules with the therapeutic power of biologics.
STX-0712 is a CyTAC targeting the GPCR CCR2, which is a selective marker expressed at high levels on pathogenic monocytes. Pathogenic monocytes expressing CCR2 have been shown to be the key drivers in some hematological malignancies. A Phase 1 trial is ongoing to assess the safety and efficacy of STX-0712 in patients with advanced CMML (NCT06950034).
Lay Abstract
For additional information, please visit https://lls.org/therapy-acceleration-program-portfolio
Program
